JP2022526015A5 - - Google Patents

Info

Publication number
JP2022526015A5
JP2022526015A5 JP2021559818A JP2021559818A JP2022526015A5 JP 2022526015 A5 JP2022526015 A5 JP 2022526015A5 JP 2021559818 A JP2021559818 A JP 2021559818A JP 2021559818 A JP2021559818 A JP 2021559818A JP 2022526015 A5 JP2022526015 A5 JP 2022526015A5
Authority
JP
Japan
Prior art keywords
pharmaceutically acceptable
disease
stereoisomers
stereoisomer
mixture
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021559818A
Other languages
English (en)
Japanese (ja)
Other versions
JP7623294B2 (ja
JP2022526015A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/027742 external-priority patent/WO2020210684A1/en
Publication of JP2022526015A publication Critical patent/JP2022526015A/ja
Publication of JP2022526015A5 publication Critical patent/JP2022526015A5/ja
Application granted granted Critical
Publication of JP7623294B2 publication Critical patent/JP7623294B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021559818A 2019-04-11 2020-04-10 化合物、組成物および方法 Active JP7623294B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962832775P 2019-04-11 2019-04-11
US62/832,775 2019-04-11
PCT/US2020/027742 WO2020210684A1 (en) 2019-04-11 2020-04-10 Compounds, compositions and methods

Publications (3)

Publication Number Publication Date
JP2022526015A JP2022526015A (ja) 2022-05-20
JP2022526015A5 true JP2022526015A5 (cg-RX-API-DMAC7.html) 2023-04-17
JP7623294B2 JP7623294B2 (ja) 2025-01-28

Family

ID=72752101

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021559818A Active JP7623294B2 (ja) 2019-04-11 2020-04-10 化合物、組成物および方法

Country Status (19)

Country Link
US (1) US12358896B2 (cg-RX-API-DMAC7.html)
EP (1) EP3953348B1 (cg-RX-API-DMAC7.html)
JP (1) JP7623294B2 (cg-RX-API-DMAC7.html)
KR (1) KR102962366B1 (cg-RX-API-DMAC7.html)
CN (1) CN113939294A (cg-RX-API-DMAC7.html)
AR (1) AR118641A1 (cg-RX-API-DMAC7.html)
AU (1) AU2020272045B2 (cg-RX-API-DMAC7.html)
BR (1) BR112021020027A2 (cg-RX-API-DMAC7.html)
CA (1) CA3136447A1 (cg-RX-API-DMAC7.html)
DK (1) DK3953348T3 (cg-RX-API-DMAC7.html)
EA (1) EA202192530A1 (cg-RX-API-DMAC7.html)
ES (1) ES3018383T3 (cg-RX-API-DMAC7.html)
IL (1) IL287120B2 (cg-RX-API-DMAC7.html)
MA (1) MA55624A (cg-RX-API-DMAC7.html)
MX (1) MX2021012392A (cg-RX-API-DMAC7.html)
SG (1) SG11202111058XA (cg-RX-API-DMAC7.html)
TW (1) TWI851710B (cg-RX-API-DMAC7.html)
WO (1) WO2020210684A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA202107499B (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3086182A1 (en) 2017-12-20 2019-06-27 Denali Therapeutics Inc. Process for the preparation of pyrimidinyl-4-aminopyrazole compounds
AU2021371697B2 (en) * 2020-10-29 2024-10-24 Suzhou Yabao Pharmaceutical R&D Co., Ltd. Substituted diarylamine compound, pharmaceutical composition thereof, preparation method therefor, and use thereof
CN116120291B (zh) * 2023-04-11 2023-06-30 英矽智能科技(上海)有限公司 吲唑类化合物及其制备方法和应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101566091B1 (ko) 2010-11-10 2015-11-04 에프. 호프만-라 로슈 아게 Lrrk2 조절제로서 피라졸 아미노피리미딘 유도체
PT3472153T (pt) * 2016-06-16 2021-12-31 Denali Therapeutics Inc Pirimidin-2-ilamino-1h-pirazóis como inibidores de lrrk2 para uso no tratamento de distúrbios neurodegenerativos
WO2018217946A1 (en) * 2017-05-24 2018-11-29 Denali Therapeutics Inc. Compounds, compositions and methods
CA3086182A1 (en) 2017-12-20 2019-06-27 Denali Therapeutics Inc. Process for the preparation of pyrimidinyl-4-aminopyrazole compounds

Similar Documents

Publication Publication Date Title
JP7515481B2 (ja) Il-17の小分子調節物質としてのアミノ酸アニリド
JP6505956B2 (ja) JAK阻害剤としてのピラゾロ[1,5−a]ピラジン−4−イル誘導体
JP7664947B2 (ja) Il-17の調節因子としてのイミダゾリダジン
JP2010506854A5 (cg-RX-API-DMAC7.html)
JP2021534124A5 (cg-RX-API-DMAC7.html)
JP2019521984A5 (cg-RX-API-DMAC7.html)
TW201840549A (zh) 2-雜芳基-3-氧代-2,3-二氫噠嗪-4-甲醯胺
JP2009526037A (ja) トリアゾロピリジン化合物
JP2015522036A5 (cg-RX-API-DMAC7.html)
JP2016510758A5 (cg-RX-API-DMAC7.html)
UA113208C2 (xx) Похідні бензаміду для інгібування активності abl1, abl2 та bcr-abl1
JP2016512515A5 (cg-RX-API-DMAC7.html)
CN102361868A (zh) 作为1-磷酸-鞘氨醇激动剂的吡唑-1,2,4-噁二唑衍生物
IL302997B2 (en) Purine inhibitors
JP2016537346A5 (cg-RX-API-DMAC7.html)
JP2018522925A5 (cg-RX-API-DMAC7.html)
ES2533095T3 (es) Agonistas de receptores de esfingosina-1-fosfato
JP2013525356A5 (cg-RX-API-DMAC7.html)
JP2019535788A5 (cg-RX-API-DMAC7.html)
JP2015502371A5 (cg-RX-API-DMAC7.html)
JP2013525490A5 (cg-RX-API-DMAC7.html)
JP2013530202A5 (cg-RX-API-DMAC7.html)
JP2022048391A (ja) インフルエンザを処置するためのオルソミクソウイルス複製の阻害剤としての10-(ジ(フェニル)メチル)-4-ヒドロキシ-8,9,9a,10-テトラヒドロ-7H-ピロロ[1’,2’:4,5]ピラジノ[1,2-b]ピリダジン-3,5-ジオン誘導体および関連化合物
CN104994851A (zh) 作为crac通道抑制剂的基于吡唑基的甲酰胺i
JP2022505827A (ja) 置換インドール二量体の化合物